<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626856</url>
  </required_header>
  <id_info>
    <org_study_id>AF/SC-08/03.0</org_study_id>
    <nct_id>NCT04626856</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection</brief_title>
  <official_title>Evaluation of the Safety and Preliminary Immunogenicity of Inactivated Rotavirus Vaccine (Vero Cell) in Healthy Population: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Provincal Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blinded, placebo-controlled, Phase 1, dose-escalation&#xD;
      study to evaluate the safety, reactogenicity and immunogenicity of Inactivated Rotavirus&#xD;
      Vaccine (IRV) performed in healthy adult (aged 18-49 years), adolescent (aged 6-17 years) and&#xD;
      infant subjects (aged 2-71 months). Primary objectives of the clinical trial include&#xD;
      assessing the safety and tolerability of IRV given at two and three dose levels and comparing&#xD;
      the safety and tolerability of IRV after each vaccination, between dosage groups, and by&#xD;
      pre-vaccination rotavirus immune status. Secondary objective of the clinical trial is&#xD;
      immunogenicity evaluation after each vaccination, between dosage groups, and by&#xD;
      pre-vaccination rotavirus immune status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial aimed to evaluate safety and immunogenicity effect of IRV（Vero cell）in&#xD;
      Chinese healthy adults, adolescents and infants. The subjects were divided into 5 groups. Two&#xD;
      dose and three dose levels will be evaluated. Adult (aged 18-49 years), adolescents (aged&#xD;
      6-17 years), infant subjects (aged 7-71 months) and infant subjects (aged 2-6 months) will&#xD;
      receive intramuscular (IM) injection on Days 0 and 28. Infant subjects (aged 2-6 months)&#xD;
      subjects will receive intramuscular (IM) injection on Days 0 , 28 and 56. Three dose&#xD;
      subgroups (low dose, medium dose and high dose were included in each age group. To maintain&#xD;
      blindness in the trial, subjects were randomized in a 3:1 ratio to receive different dosages&#xD;
      of the vaccine group or placebo group. In the analysis, the placebo subjects of the same age&#xD;
      group were combined to ensure that the analysis ratio of the experimental vaccine group to&#xD;
      the placebo group is 1:1. Therefore, 24 subjects in the experimental vaccine group and 8&#xD;
      subjects in the placebo group were chose in each dose group. Subjects were randomized to&#xD;
      receive different dosages of the vaccine or placebo. Vaccination was performed in the adult&#xD;
      group first, then on the adolescents, and on the infants last. Within each age group,&#xD;
      dose-escalation with the principle from low to high dosage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>0-30 minutes after the first dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the first dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>0-30 minutes after the second dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the second dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>0-30 minutes after the third dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the third dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal blood biochemistry assessment</measure>
    <time_frame>Day 4 after the first dose vaccination</time_frame>
    <description>Incidence of abnormal blood biochemistry assessment at Day 4 after the first dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal blood routine assessment</measure>
    <time_frame>Day 4 after the first dose vaccination</time_frame>
    <description>Incidence of abnormal blood routine assessment at Day 4 after the first dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal urine routine assessment</measure>
    <time_frame>Day 4 after the first dose vaccination</time_frame>
    <description>Incidence of abnormal urine routine assessment at Day 4 after the first dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal blood biochemistry assessment</measure>
    <time_frame>Day 4 after the second dose vaccination</time_frame>
    <description>Incidence of abnormal blood biochemistry assessment at Day 4 after the second dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal blood routine assessment</measure>
    <time_frame>Day 4 after the second dose vaccination</time_frame>
    <description>Incidence of abnormal blood routine assessment at Day 4 after the second dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal urine routine assessment</measure>
    <time_frame>Day 4 after the second dose vaccination</time_frame>
    <description>Incidence of abnormal urine routine assessment at Day 4 after the second dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal blood biochemistry assessment</measure>
    <time_frame>Day 4 after the third dose vaccination</time_frame>
    <description>Incidence of abnormal blood biochemistry assessment at Day 4 after the third dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal blood routine assessment</measure>
    <time_frame>Day 4 after the third dose vaccination</time_frame>
    <description>Incidence of abnormal blood routine assessment at Day 4 after the third dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of abnormal urine routine assessment</measure>
    <time_frame>Day 4 after the third dose vaccination</time_frame>
    <description>Incidence of abnormal urine routine assessment at Day 4 after the third dose vaccination, except children aged Month 2-71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>Day 0 to7 after the first dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the first dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>Day 8 to30 after the first dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the first dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>Day 0 to7 after the second dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the second dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>Day 8 to30 after the second dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the second dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>Day 0 to7 after the third dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the third dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions/events</measure>
    <time_frame>Day 8 to30 after the third dose vaccination</time_frame>
    <description>Incidence of adverse reactions/events after the third dose vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of serious adverse events</measure>
    <time_frame>From the beginning of the vaccination to 6 months after the last vaccination completed</time_frame>
    <description>Occurrence of serious adverse reactions/events after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-seroconversion rates of neutralizing antibody</measure>
    <time_frame>Day 28 after the second dose vaccination</time_frame>
    <description>Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seroconversion will be defined as a change from seronegative (&lt;1:8) to seropositive (≥1:8), or ≥4-fold increase from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-seroconversion rates of neutralizing antibody</measure>
    <time_frame>Day 28 after the third dose vaccination</time_frame>
    <description>Neutralizing antibody assay will be performed using the neutralization and ELISA method. Seroconversion will be defined as a change from seronegative (&lt;1:8) to seropositive (≥1:8), or ≥4-fold increase from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody</measure>
    <time_frame>Day 28, 90, 180 after the second dose vaccination</time_frame>
    <description>Neutralizing antibody assay will be performed using the neutralization and ELISA method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody</measure>
    <time_frame>Day 28, 90, 180 after the third dose vaccination</time_frame>
    <description>Neutralizing antibody assay will be performed using the neutralization and ELISA method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity index-seroconversion rates of IgA antibody</measure>
    <time_frame>Day 28 after the second vaccination</time_frame>
    <description>IgA antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (&lt;1:8) to seropositive (≥1:8), or ≥4-fold increase from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-seroconversion rates of IgA antibody</measure>
    <time_frame>Day 28 after the third dose vaccination</time_frame>
    <description>IgA antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (&lt;1:8) to seropositive (≥1:8), or ≥4-fold increase from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-geometric mean titer (GMT) of IgA antibody</measure>
    <time_frame>Day 28, 90, 180 after the second dose vaccination</time_frame>
    <description>IgA antibody assay will be performed using the ELISA method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-geometric mean titer (GMT) of IgA antibody</measure>
    <time_frame>Day 28, 90, 180 after the third dose vaccination</time_frame>
    <description>IgA antibody assay will be performed using the ELISA method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-seroconversion rates of IgG antibody</measure>
    <time_frame>Day 28 after the second dose vaccination</time_frame>
    <description>IgG antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (&lt;1:8) to seropositive (≥1:8), or ≥4-fold increase from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-seroconversion rates of IgG antibody</measure>
    <time_frame>Day 28 after the third dose vaccination</time_frame>
    <description>IgG antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (&lt;1:8) to seropositive (≥1:8), or ≥4-fold increase from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-geometric mean titer (GMT) of IgG antibody</measure>
    <time_frame>Day 28, 90, 180 after the second dose vaccination</time_frame>
    <description>IgG antibody assay will be performed using the ELISA method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-geometric mean titer (GMT) of IgG antibody</measure>
    <time_frame>Day 28, 90, 180 after the third dose vaccination</time_frame>
    <description>IgG antibody assay will be performed using the ELISA method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cellular immune responses of lymphocytes</measure>
    <time_frame>Day 14 after the second vaccination</time_frame>
    <description>Lymphocytes (NK cells, B lymphocytes and T lymphocyte) responses of children aged 7-71 months will be measured using Flow cytometry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cellular immune responses of cytokines</measure>
    <time_frame>Day 14 after the second vaccination</time_frame>
    <description>Cytokines (IL-2, IL-4, IL-6, IL-10, TNF - α and IFN - γ) responses of children aged 7-71 months will be measured using ELISA method.</description>
  </other_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Rotavirus Infection</condition>
  <arm_group>
    <arm_group_label>Low dosage in adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage in adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage in adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage in adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage in adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage in adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage in infants (7-71 months old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage in infants (7-71 months old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage in infants (7-71 months old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage in infants (2-6 months old, two-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage in infants (2-6 months old, two-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage in infants (2-6 months old, two-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage in infants (2-6 months old, three-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage in infants (2-6 months old, three-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage in infants (2-6 months old, three-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo on day 0, 28</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two doses of placebo at the vaccination schedule of day 0,28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo on day 0, 28, 56</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three doses of placebo at the vaccination schedule of day 0, 28,56</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28</description>
    <arm_group_label>Low dosage in adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28</description>
    <arm_group_label>Medium dosage in adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28</description>
    <arm_group_label>High dosage in adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28</description>
    <arm_group_label>Low dosage in adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28</description>
    <arm_group_label>Medium dosage in adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28</description>
    <arm_group_label>High dosage in adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28</description>
    <arm_group_label>Low dosage in infants (7-71 months old)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28</description>
    <arm_group_label>Medium dosage in infants (7-71 months old)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28</description>
    <arm_group_label>High dosage in infants (7-71 months old)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28</description>
    <arm_group_label>Low dosage in infants (2-6 months old, two-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28</description>
    <arm_group_label>Medium dosage in infants (2-6 months old, two-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dosage IRV on a 0- and 28-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28</description>
    <arm_group_label>High dosage in infants (2-6 months old, two-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dosage IRV on a 0- , 28- and 56-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56</description>
    <arm_group_label>Low dosage in infants (2-6 months old, three-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium dosage IRV on a 0- , 28- and 56-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56</description>
    <arm_group_label>Medium dosage in infants (2-6 months old, three-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dosage IRV on a 0- , 28- and 56-day schedule</intervention_name>
    <description>Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56</description>
    <arm_group_label>High dosage in infants (2-6 months old, three-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo on day 0, 28</intervention_name>
    <description>Two doses of placebo at the vaccination schedule of day 0,28</description>
    <arm_group_label>Placebo on day 0, 28</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo on day 0, 28, 56</intervention_name>
    <description>Three doses of placebo at the vaccination schedule of day 0, 28,56</description>
    <arm_group_label>Placebo on day 0, 28, 56</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 2 months old to 49 years old, healthy resident, excluding the following:&#xD;
&#xD;
               -  Congenital malformations, developmental disorders, genetic defects, severe&#xD;
                  malnutrition and other conditions；&#xD;
&#xD;
               -  Have Congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia,&#xD;
                  systemic lupus Erythematosus (SLE) , juvenile Rheumatoid Arthritis, or other&#xD;
                  autoimmune diseases；&#xD;
&#xD;
               -  History of Cerebral Palsy, seizures, mental illness.&#xD;
&#xD;
          2. I and/or my guardian voluntarily participate and sign an informed consent form, and&#xD;
             can follow the requirements of the clinical trial protocol;&#xD;
&#xD;
          3. Have never received oral rotavirus live attenuated vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  First dose exclusion criteria:&#xD;
&#xD;
               1. Armpit temperature &gt;37.0℃ before vaccination；&#xD;
&#xD;
               2. Subjects with history of intussusception or suffering from intussusception；&#xD;
&#xD;
               3. Subjects with history of convulsions and convulsions; history of epilepsy, mental&#xD;
                  illness and their family history；&#xD;
&#xD;
               4. Subjects with history of allergy to vaccination；&#xD;
&#xD;
               5. Acute attacks of various acute diseases (fever) or chronic diseases within 3 days&#xD;
                  before receiving the study vaccine；&#xD;
&#xD;
               6. Subjects receiving immune enhancement or immunosuppressive therapy within 3&#xD;
                  months (continuous oral or infusion for more than 14 days)；&#xD;
&#xD;
               7. Subjects vaccinated with live attenuated vaccine within 14 days and other&#xD;
                  vaccines within 7 days before vaccination；&#xD;
&#xD;
               8. Subjects with history of coagulation dysfunction (e.g. Coagulation factor&#xD;
                  deficiency, coagulation disease);&#xD;
&#xD;
               9. Subjects with primary and secondary immunocompromised (history of thyroid,&#xD;
                  pancreas, liver, spleen resection, or need for treatment for thyroid disease in&#xD;
                  the past 12 months)；&#xD;
&#xD;
              10. Subjects with abnormal blood biochemistry, blood routine, and urine routine&#xD;
                  related indicators that have clinical significance* before vaccination；&#xD;
&#xD;
              11. Subjects who are currently or plan to participate in other clinical studies;&#xD;
&#xD;
              12. According to the investigator's judgment, the subject has any other factors that&#xD;
                  are not suitable for participating in the clinical trial.&#xD;
&#xD;
                  Note*: The criterion of no clinical significance is &quot;the laboratory test value&#xD;
                  between the upper limit (ULN) or lower limit (LLN) of the reference value range&#xD;
                  and the grade 1 adverse event&quot; as judged by the doctor to have no clinical&#xD;
                  significance.&#xD;
&#xD;
          -  In addition to the general exclusion criteria, specific subjects should also follow&#xD;
             the following exclusion criteria.&#xD;
&#xD;
        （1）18-49-year-old women who have plans to become pregnant within the past 2 months or are&#xD;
        pregnant or are breastfeeding； （2）Positive pregnancy test of female subjects of&#xD;
        childbearing age； （3）18-49-year-old adults with hypertension that cannot be controlled by&#xD;
        drugs (on site measurement: systolic blood pressure ≥140mmHg or diastolic blood pressure&#xD;
        ≥90mmHg)； （4）24-month-old infant subjects with a history of dystocia, suffocation rescue,&#xD;
        neurological damage； （5）24-month-old baby subjects are born prematurely (delivered after&#xD;
        the 37th week of pregnancy), low weight (birth weight for girls &lt;2300g, boys &lt;2500g).&#xD;
&#xD;
        -Exclusion criteria for follow-up needle:&#xD;
&#xD;
          1. Subjects with serious adverse reaction after the previous vaccination;&#xD;
&#xD;
          2. For the subjects who are newly discovered or newly appeared after the first&#xD;
             vaccination that do not meet the selection criteria or meet the first exclusion&#xD;
             criteria, the investigator will determine whether the subjects continue to participate&#xD;
             the clinical trial;&#xD;
&#xD;
          3. Subjects vaccinated with other rotavirus vaccines other than the research vaccine&#xD;
             during the study period;&#xD;
&#xD;
          4. Other exclusion reasons considered by the researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongjun Li, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henan Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Zhenzhou</city>
        <state>Henan</state>
        <zip>450016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Li Hongjun</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

